When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BYSI - BeyondSpring's lead drug successful in late-stage neutropenia study
BeyondSpring Inc.
BeyondSpring (NASDAQ:BYSI) announces positive results from a Phase 3 clinical trial, PROTECTIVE-2, evaluating lead candidate Plinabulin, combined with Amgen's (NASDAQ:AMGN) Neulasta (pegfilgrastim) compared to Neulasta alone for the treatment of chemo-induced neutropenia (low levels of white blood cells called neutrophils).
More news on: BeyondSpring Inc., Amgen Inc., Healthcare stocks news, Stocks on the move,